MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 593104 | Name: Acetoxycycloheximide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Acetoxycycloheximide induces cell surface TNF receptor 1. It also rapidly induces apoptosis mediated by the release of cytochrome c via activation of c-Jun N-terminal kinase.

Chemical Structure

Acetoxycycloheximide
Acetoxycycloheximide
CAS#2885-39-4

Theoretical Analysis

MedKoo Cat#: 593104

Name: Acetoxycycloheximide

CAS#: 2885-39-4

Chemical Formula: C17H25NO6

Exact Mass: 339.1682

Molecular Weight: 339.39

Elemental Analysis: C, 60.16; H, 7.43; N, 4.13; O, 28.28

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Acetoxycycloheximide
IUPAC/Chemical Name
2,6-Piperidinedione, 4-(2-(5-(acetyloxy)-3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl)-, (1S-(1alpha(S*),3alpha,5alpha))- (9CI)
InChi Key
UFDHNJJHPSGMFX-MMAROODPSA-N
InChi Code
InChI=1S/C17H25NO6/c1-9-7-17(3,24-10(2)19)8-12(16(9)23)13(20)4-11-5-14(21)18-15(22)6-11/h9,11-13,20H,4-8H2,1-3H3,(H,18,21,22)/t9-,12-,13?,17+/m0/s1
SMILES Code
O=C(CC(CC([C@H]1C([C@@H](C)C[C@@](C)(OC(C)=O)C1)=O)O)C2)NC2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 339.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Samur DN, Arslan R, Aydın S, Bektas N. Valnoctamide: The effect on relieving of neuropathic pain and possible mechanisms. Eur J Pharmacol. 2018 May 15;827:208-214. doi: 10.1016/j.ejphar.2018.03.006. Epub 2018 Mar 6. PubMed PMID: 29522726. 2: Younus I, Reddy DS. A resurging boom in new drugs for epilepsy and brain disorders. Expert Rev Clin Pharmacol. 2018 Jan;11(1):27-45. doi: 10.1080/17512433.2018.1386553. Epub 2017 Oct 23. Review. PubMed PMID: 28956955. 3: Kudin AP, Mawasi H, Eisenkraft A, Elger CE, Bialer M, Kunz WS. Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase. Int J Mol Sci. 2017 Sep 6;18(9). pii: E1912. doi: 10.3390/ijms18091912. PubMed PMID: 28878165; PubMed Central PMCID: PMC5618561. 4: Ornaghi S, Hsieh LS, Bordey A, Vergani P, Paidas MJ, van den Pol AN. Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities. J Neurosci. 2017 Jul 19;37(29):6877-6893. doi: 10.1523/JNEUROSCI.0970-17.2017. Epub 2017 Jun 19. PubMed PMID: 28630251; PubMed Central PMCID: PMC5518418. 5: Weiser M, Levi L, Levine SZ, Bialer M, Shekh-Ahmad T, Matei V, Tiugan A, Cirjaliu D, Sava C, Sinita E, Zamora D, Davis JM. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disord. 2017 Jun;19(4):285-294. doi: 10.1111/bdi.12506. Epub 2017 Jun 12. PubMed PMID: 28605109. 6: Modi HR, Ma K, Chang L, Chen M, Rapoport SI. Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder. Psychiatry Res. 2017 Aug;254:279-283. doi: 10.1016/j.psychres.2017.04.048. Epub 2017 Apr 26. PubMed PMID: 28500975; PubMed Central PMCID: PMC5524208. 7: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017 Feb;58(2):181-221. doi: 10.1111/epi.13634. Epub 2017 Jan 23. Review. PubMed PMID: 28111749. 8: Ornaghi S, Davis JN, Gorres KL, Miller G, Paidas MJ, van den Pol AN. Mood stabilizers inhibit cytomegalovirus infection. Virology. 2016 Dec;499:121-135. doi: 10.1016/j.virol.2016.09.012. Epub 2016 Sep 19. PubMed PMID: 27657833; PubMed Central PMCID: PMC5102808. 9: Rosa M, Bonnaillie P, Chanteux H. Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition. Xenobiotica. 2016 Dec;46(12):1076-1084. Epub 2016 Mar 3. PubMed PMID: 26936324. 10: Trinka E, Brigo F, Shorvon S. Recent advances in status epilepticus. Curr Opin Neurol. 2016 Apr;29(2):189-98. doi: 10.1097/WCO.0000000000000307. Review. PubMed PMID: 26886360. 11: Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. Pharmacol Res. 2016 Feb;104:38-48. doi: 10.1016/j.phrs.2015.12.011. Epub 2015 Dec 12. Review. PubMed PMID: 26689774. 12: Wlodarczyk BJ, Ogle K, Lin LY, Bialer M, Finnell RH. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord. 2015 Sep;17(6):615-25. doi: 10.1111/bdi.12325. Epub 2015 Aug 20. PubMed PMID: 26292082; PubMed Central PMCID: PMC4631615. 13: Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav. 2015 Aug;49:298-302. doi: 10.1016/j.yebeh.2015.04.012. Epub 2015 May 13. Review. PubMed PMID: 25979572. 14: Mawasi H, Shekh-Ahmad T, Finnell RH, Wlodarczyk BJ, Bialer M. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid. Epilepsy Behav. 2015 May;46:72-8. doi: 10.1016/j.yebeh.2015.02.040. Epub 2015 Apr 8. PubMed PMID: 25863940. 15: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015 Mar;111:85-141. doi: 10.1016/j.eplepsyres.2015.01.001. Epub 2015 Jan 19. Review. PubMed PMID: 25769377. 16: Bar-Klein G, Swissa E, Kamintsky L, Shekh-Ahmad T, Saar-Ashkenazy R, Hubary Y, Shrot S, Stetlander L, Eisenkraft A, Friedman A, Bialer M. sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia. 2014 Dec;55(12):1953-8. doi: 10.1111/epi.12838. Epub 2014 Nov 6. PubMed PMID: 25377630. 17: Modi HR, Basselin M, Rapoport SI. Valnoctamide, a non-teratogenic amide derivative of valproic acid, inhibits arachidonic acid activation in vitro by recombinant acyl-CoA synthetase-4. Bipolar Disord. 2014 Dec;16(8):875-80. doi: 10.1111/bdi.12220. Epub 2014 Jul 8. PubMed PMID: 25041123; PubMed Central PMCID: PMC4554599. 18: Spampanato J, Dudek FE. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia. 2014 Sep;55(9):e94-8. doi: 10.1111/epi.12702. Epub 2014 Jul 3. PubMed PMID: 24995528; PubMed Central PMCID: PMC4167227. 19: Shekh-Ahmad T, Hen N, Yagen B, McDonough JH, Finnell RH, Wlodarczyk BJ, Bialer M. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia. 2014 Feb;55(2):353-61. doi: 10.1111/epi.12480. Epub 2013 Dec 6. PubMed PMID: 24313671; PubMed Central PMCID: PMC4963464. 20: Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia. 2013 Sep;54 Suppl 6:99-102. doi: 10.1111/epi.12290. PubMed PMID: 24001086.